Proscia
- Company typePrivate
- Founded2014
- HeadquartersPhiladelphia, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
Proscia firmographics
Firmographics- Name
- Proscia
- Legal name
- Proscia Inc.
- Website
- https://proscia.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Proscia industry classification
Industry- Product category
- Digital Pathology Software
- NAICS
- Software Publishers (513210)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where Proscia is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Proscia business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Enterprise SaaS subscriptions (Concentriq platform): Recurring subscription revenue from Concentriq AP, AP-Dx, and Concentriq LS deployed at diagnostic laboratories, academic medical centers, health systems, CROs, and biopharmaceutical companies. Cloud-native SaaS pricing is quote-based and not publicly disclosed. Customers include 16 of the top 20 pharma companies and 4,000+ hospitals/clinics globally.
- Professional services and implementation: Tailored implementations delivered by Proscia's Professional Services team: deployment architecture, image and data migration, scanner/LIS integration, and workflow redesign. Includes 24/7 support, expert clinical/operational consulting, and bespoke onboarding plans for enterprise customers.
- Real-world data and biopharma partnerships: Revenue from enabling laboratories to share de-identified real-world data with biopharma partners on Concentriq (Aperture network) — including clinical trial matching, companion diagnostic development, and biomarker validation programs. PathGroup cited >$1M new revenue from existing case volume using Concentriq.
- AI application and platform marketplace revenue: Concentriq Compute managed AI deployment service, and AI companion diagnostic commercialization with revenue-share arrangements enabling precision medicine organizations to co-develop and monetize AI products alongside Proscia.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise quote-based SaaS — Concentriq demo and custom pricing per workflow |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels12 records
Proscia product offering
Product offeringCore offering
Proscia develops and sells Concentriq, an enterprise pathology AI platform that enables laboratories, health systems, academic medical centers, contract research organizations (CROs), and biopharmaceutical companies to manage, analyze, and derive insights from whole-slide pathology images and associated clinical, molecular, and genomic data. The platform is offered in distinct configurations (Concentriq AP-Dx for primary clinical diagnosis, Concentriq AP and Concentriq LS for Research Use Only) and is delivered as cloud-native SaaS with integrations to scanners, LIS systems, and 230+ interoperable AI applications.
Product overview
Proscia's offering is a single underlying pathology AI platform branded Concentriq, delivered as a portfolio of distinct configurations rather than separate products. Concentriq AP-Dx is FDA 510(k)-cleared in the U.S. (with the Hamamatsu NanoZoomer S360MD Slide scanner), CE-IVDR marked in the EU, licensed in Canada, and authorized in the UK for primary clinical diagnosis, while Concentriq AP and Concentriq LS are Research Use Only products for prospective workflows and life sciences research. The latest release, Concentriq Fifth Generation, layers an AI-native architecture with frontier vision, language, and multimodal models across all configurations. Sitting on top of this platform are two adjacent offerings: Proscia Aperture, a real-world multimodal data network that connects Concentriq to cohorts of AI-enriched tissue images, molecular, clinical, and genomic data from nearly 4,000 hospitals and clinics, and Concentriq Compute, a fully managed compute service for deploying customer AI models alongside Concentriq data. Together, these products support biomarker discovery, clinical development, companion diagnostics, and case review, and are used by 16 of the top 20 pharmaceutical companies and over 4,000 hospitals and clinics globally.
Differentiator
Problem solved
Functional benefit
Brands
- Concentriq: Pathology AI platform (portfolio including Concentriq AP-Dx for primary clinical diagnosis, Concentriq AP and Concentriq LS for Research Use Only) — the company's flagship product brand.
- Concentriq AP-Dx
- Concentriq AP
- Concentriq LS
- Proscia Aperture
Products and services
- Concentriq (platform) Enterprise pathology AI platform that powers precision medicine from discovery through diagnosis with purpose-built solutions for biomarker research, clinical trials, companion diagnostics, and case review. The Concentriq portfolio is a single underlying platform offered in distinct configurations.
- Concentriq AP-Dx Regulatory-cleared configuration of the Concentriq platform for primary clinical diagnosis. FDA 510(k)-cleared in the U.S., CE-IVDR marked in the EU, licensed in Canada, and authorized in the UK. Built on the same technology as Concentriq AP but cleared for diagnostic use.
- Concentriq AP Research Use Only configuration of the Concentriq platform; powers Proscia's interoperable AI applications and native AI features for research workflows. Not for use in diagnostic procedures.
- Concentriq LS Life sciences configuration of the Concentriq platform for biomarker discovery, clinical development, and companion diagnostics workflows. For Research Use Only; not for use in diagnostic procedures.
- Concentriq Fifth Generation Latest generation of the Concentriq platform built on a new AI-native architecture with frontier vision, language, and multimodal models at the core. Introduces unified intelligence across images, metadata, and clinical/scientific context for biomarker discovery, clinical development, companion diagnostics, and case review.
- Proscia Aperture Real-world multimodal data network that brings AI-enriched tissue images, molecular, clinical, and genomic data from nearly 4,000 hospitals and clinics into Concentriq as cohorts or real-time insights, enabling validation against real-world variation and supporting biomarker discovery.
- Concentriq Compute Fully managed compute service that takes AI models from ready to running in days with no infrastructure to stand up and with IP retained by the customer; executes containerized model workloads right beside Concentriq data.
Companies that use Proscia
Customer profileNamed customers23 records
Segments5 records
Ideal customer profiles4 records
Proscia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration12 records
AI capability12 records
Feature9 records
Proscia partnerships and signals
Strategic signalScale indicators28 records
Recent moves6 records
Expansion highlights6 records
Proscia competitors and assessment
Company assessmentEmerging players
- Owkin: AI-for-biotech company applying multimodal AI to pathology and clinical data, with biopharma R&D and CDx partnerships. Comparable to Proscia in the biopharma/AI-for-pathology overlap, though more research-oriented than clinical-platform focused.
Direct peers
- Paige: AI pathology company with FDA-authorized cancer detection products and enterprise deployments across healthcare and life sciences. Comparable to Proscia as a direct competitor in clinical AI pathology and biopharma biomarker programs.
- Mindpeak: AI image analysis vendor whose applications run natively inside the Concentriq viewer. Directly comparable as a peer/partner providing biomarker quantification (e.g., PD-L1, HER2, Ki-67) in clinical pathology workflows.
- Indica Labs: Digital pathology software vendor (HALO platform) used widely in pharma and academic research for whole-slide image analysis. Comparable to Proscia as a direct competitor in life-sciences pathology software and AI-driven image analysis.
- PathAI: AI-native digital pathology platform serving both biopharma and clinical diagnostics with proprietary foundation models. Directly comparable to Proscia across pharma biomarker discovery, AI-based CDx, and clinical pathology deployments.
- Ibex Medical Analytics: AI-powered cancer diagnostics platform (Galen) deployed in clinical pathology workflows and also interoperable with Proscia via the Ready partner program. Directly comparable as an AI pathology vendor serving clinical labs and reference labs.
- Aiforia Technologies: AI-powered image analysis platform for pathology, integrated with Proscia Concentriq via a 2026 non-exclusive partnership. Comparable as a direct competitor/partner offering AI diagnostic applications for clinical and research pathology.
- Visiopharm: Quantitative digital pathology and AI image analysis platform interoperable with Concentriq. Directly comparable as a peer/partner providing biomarker quantification and AI scoring for clinical and translational pathology workflows.
Broad incumbents
- Philips Digital Pathology (IntelliSite Pathology Solution): Enterprise digital pathology platform from a large diversified medtech incumbent, with scanner, viewer, and workflow components. Comparable to Proscia as a broad incumbent competitor in primary-diagnosis digital pathology deployments.
- Roche Digital Pathology (VENTANA / uPath): Broad incumbent in anatomic pathology combining slide scanners, staining reagents, and the uPath enterprise software platform. Comparable to Proscia as a major competitor in primary-diagnosis digital pathology, with a much larger installed base in clinical labs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks5 records
Key highlights7 records
Customer concentration
Proscia social profiles
Digital presenceProscia compliance and trust
Trust signalCompliance8 records
Proscia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Proscia leadership team
Management profileNumber of profiles
Profiles5 records
Proscia funding detail
Funding detailFunding overview
Funding rounds7 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Proscia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Proscia
What does Proscia do?
Proscia develops and sells Concentriq, an enterprise pathology AI platform that enables laboratories, health systems, academic medical centers, contract research organizations (CROs), and biopharmaceutical companies to manage, analyze, and derive insights from whole-slide pathology images and associated clinical, molecular, and genomic data. The platform is offered in distinct configurations (Concentriq AP-Dx for primary clinical diagnosis, Concentriq AP and Concentriq LS for Research Use Only) and is delivered as cloud-native SaaS with integrations to scanners, LIS systems, and 230+ interoperable AI applications.
Is Proscia a public or private company?
Proscia is a private company. It is classified as venture growth investor backed and is currently operating.
When was Proscia founded?
Proscia was founded in 2014. It employs 101 to 250 people.
Where is Proscia based?
Proscia is headquartered in Philadelphia, United States, in the North America region.
How does Proscia make money?
Four revenue lines are on record. Enterprise SaaS subscriptions (Concentriq platform) is the primary driver. The others are professional services and implementation, real-world data and biopharma partnerships and AI application and platform marketplace revenue.
Who are Proscia's main competitors?
Owkin is listed as an emerging player. Direct peers are Paige, Mindpeak, Indica Labs, PathAI, Ibex Medical Analytics, Aiforia Technologies and Visiopharm. Broad incumbents are Philips Digital Pathology (IntelliSite Pathology Solution) and Roche Digital Pathology (VENTANA / uPath).
Does Proscia have an API?
Yes. Proscia offers open APIs including REST API, Custom APIs, SDK, and Model Context Protocol (MCP). Image analysis models integrate through an API that posts results back as overlays, heatmaps, and structured values that display consistently to users in the Concentriq viewer. Every Concentriq service is an open API, enabling models and agents built by teams to plug in without a new integration each time. Concentriq Compute is a fully managed compute service for running AI models as containerized workloads beside data, with embeddings from frontier pathology models exposed via API. Analysis API enables programmatic model execution. Data stays accessible and portable through APIs and MCP, running on storage built for scale.
What industry is Proscia in?
Proscia's product category is Digital Pathology Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 513210 and its SIC code is 7372.